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GHF-1 is a member of the POU family of homeodomain proteins. It is a cell-type-specific transcription factor
responsible for determination and expansion of growth hormone (GH)- and prolactin-expressing cells in the
anterior pituitary. It was previously suggested that cyclic AMP (cAMP)-responsive protein kinase A (PKA)
phosphorylates GHF-1 at a site within the N-terminal arm of its homeodomain, thereby inhibiting its binding
to the GH promoter. These results, however, are inconsistent with the physiological stimulation of GH
production by the cAMP pathway. As reported here, cAMP agonists and PKA do not inhibit GHF-1 activity in
living cells and although they stimulate the phosphorylation of GHF-1, the inhibitory phosphoacceptor site
within the homeodomain is not affected. Instead, this site, Thr-220, is subject to M-phase-specific phosphor-
ylation. As a result, GHF-1 DNA binding activity is transiently inhibited during the M phase. This activity is
regained once cells enter G1, a phase during which GHF-1 phosphorylation is minimal. Thr-220 of GHF-1 is
the homolog of the mitotic phosphoacceptor site responsible for the M-phase-specific inhibition of Oct-1 DNA
binding Ser-382. As this site is conserved in all POU proteins, it appears that all members of this group are
similarly regulated. A specific kinase activity distinct in its substrate specificity and susceptibility to inhibitors
from the Cdc2 mitotic kinase or PKA was identified in extracts of mitotic cells. This novel activity could be
involved in regulating the DNA binding activity of all POU proteins in a cell cycle-dependent manner.
GHF-1 (Pit-1) is a cell-type-specific transcription factor orig-
inally identified by its ability to activate the growth hormone
(GH) gene promoter when added to HeLa cell extracts (4).
This 33-kDa protein is a member of the POU group of homeo-
domain proteins (3, 15) and thus contains a DNA binding
domain composed of a POU-specific domain and a POU ho-
meodomain (13). While the POU homeodomain is the mini-
mal region required for sequence-specific DNA binding (34),
the POU-specific domain contributes to high-affinity binding
and participates in sequence recognition (16). A similar mode
of DNA interaction is displayed by the Oct-1 POU domain
protein (1, 20, 33, 38). Although it has been suggested that
GHF-1 homodimerizes in solution and can also form het-
erodimers with Oct-1 (39, 40), most of these interactions have
been found to be DNA dependent (21) and the predominant
mode of DNA binding most likely involves cooperative binding
of two GHF-1 molecules to each binding site composed of two
half sites positioned one helical turn apart from each other, in
a head-to-tail manner (reviewed in reference 36). These con-
clusions are consistent with the three-dimensional structure of
the Oct-1 DNA binding domain-octamer site complex (19).
In addition to the GH gene, GHF-1 is responsible for acti-
vation of the prolactin (PRL) gene (6, 22, 37) and for auto-
regulatory activation of its own promoter (27). GHF-1 may
also be involved in the activation of the gene encoding the b
subunit of thyroid-stimulating hormone (22, 24). All of these
genes are expressed exclusively in specific cell types of the
anterior pituitary, which are also the site of GHF-1 expression
(11, 32). In addition to its role in target gene activation, GHF-1
is required for expansion of committed somatotropes and lac-
totropes, which synthesize GH and PRL, respectively, during
anterior pituitary development (6, 24). Although GHF-1 is
necessary for GH and PRL expression (6, 22), it is insufficient
for activation of either gene. Most somatotropes express only
GH, and most lactotropes express only PRL, yet both cell types
express similar amounts of functional GHF-1 (3, 18a). This
suggests that additional factors, acting either positively or neg-
atively, are responsible for selective activation of the GH and
PRL genes in two related, yet distinct, cell types.
It was suggested that the target gene specificity of GHF-1
may be modified by its phosphorylation, as in vitro phosphor-
ylation by cyclic AMP-responsive protein kinase A (PKA) in-
hibited the binding of GHF-1 to its high-affinity binding site
within the GH promoter and had either a weak inhibitory
effect, no effect, or a modest stimulatory effect on its binding to
several lower-affinity sites derived from the PRL gene (17).
These findings, however, are inconsistent with the known phys-
iological regulation of GH gene expression (reviewed in refer-
ence 36). GH production is stimulated by the GH-releasing
factor, a hormone which elevates the intracellular level of
cyclic AMP in somatotropes (31). The GH-releasing factor
stimulates GH transcription, as do cyclic AMP analogs (2), and
the cis element which mediates this effect overlaps with the
GHF-1 binding sites of the GH promoter (8, 9).
Phosphorylation was also found to inhibit the DNA binding
activity of another POU protein, Oct-1, and the phosphoac-
ceptor site that mediates this effect, Ser-385, is homologous to
the phosphoacceptor site responsible for inhibition of DNA
binding by GHF-1, Thr-220 (30). Although in vivo Oct-1 is
likely to be phosphorylated by a mitotic protein kinase, in vitro
Ser-385 is phosphorylated by PKA (30). Interestingly, this
phosphoacceptor site is conserved in all POU domain proteins
(17) and is located in the N-terminal arm of the POU homeo-
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domain (19). Since this residue does not appear to be directly
involved in contacting the DNA (19), its function is most likely
regulatory. The conservation of this residue in all POU pro-
teins suggests that this regulatory function is of general impor-
tance. In light of the contradictory effects of PKA on GH gene
transcription and on GHF-1 DNA binding activity, we reinves-
tigated the regulation of GHF-1 phosphorylation. We found
that in vitro, the protein can indeed be phosphorylated by PKA
at Thr-220 and that phosphorylation of this site inhibits its
binding to DNA. However, this inhibition indiscriminately af-
fected the binding of GHF-1 to all of the target sites that were
tested. Although activation of PKA in vivo resulted in in-
creased GHF-1 phosphorylation, the inhibitory phosphoaccep-
tor site was hardly affected and GHF-1-dependent transacti-
vation was not inhibited. Rather, we found that like Oct-1,
GHF-1 was phosphorylated at Thr-220 only during the M
phase, resulting in transient inhibition of its DNA binding
activity during that phase. Extracts of mitotic cells contain an
activity that phosphorylates GHF-1 at the same sites phosphor-
ylated during the M phase in vivo, including Thr-220. This
activity is different from PKA and cyclin-dependent kinases
and could be responsible for the mitotic phosphorylation of all
POU proteins.
MATERIALS AND METHODS
Cell culture and synchronization.GH3 cells were grown in Dulbecco modified
Eagle’s medium (DMEM) supplemented with 10% horse serum and 2.5% fetal
calf serum. HeLa and CV1 cells were grown in DMEM plus 10% fetal calf serum.
All cell cultures were incubated at 378C with 5% CO2.
Exponentially growing cultures of GH3 cells were synchronized at the begin-
ning of the S phase by incubation with 2 mM thymidine for 14 h. Cells were
released from this block by three washes with DMEM at 378C and placed back
into complete medium. When populations enriched in mitotic cells were desired,
5 h after release of the thymidine block, cell layers were extensively washed with
DMEM at 378C to remove unattached cells, nocodazole (40 ng/ml) was added,
and the cells were incubated for 3 h. Mitotic cells were then collected by rocking
and gentle washing of the plates with medium without detachment of the cell
monolayer. A similar synchronization protocol was applied to HeLa cells, except
that nocodazole was added 8 h after release of the thymidine block.
Flow cytometric analysis was performed with samples of 106 cells. Cells were
pelleted, suspended dropwise in 300 ml of ice-cold ethanol while vortexing,
washed twice with phosphate-buffered saline (PBS), suspended in 850 ml of PBS
containing 5 mg of RNase A per ml, and incubated for 30 min at room temper-
ature. Cells were stained by adding 125 ml of a propidium iodide solution (50 mg
of propidium iodide per ml in 50 mM sodium citrate [pH 7.2], 0.1% Triton
X-100) and analyzed on a Becton Dickinson FACScan flow cytometer by using
Lysis II software.
Protein preparation and electrophoretic mobility shift assays. A HindIII-NotI
fragment from the plasmid RSV-GHF-1 (35) was subcloned into pBluescript
(SK2) to generate a pBS-GHF-1 construct. Single-stranded DNA from this
construct was used as a template for oligonucleotide-directed in vitro mutagen-
esis with the Amersham kit. The oligonucleotides used to convert Ser-115 and
Thr-220 into alanine residues were 59-CCACCAATTTAGCTTTCCGCCTG-39
and 59-CGATACTGATAGCTGTCCTCCGT-39, respectively. Point mutations
were confirmed by DNA sequencing. BamHI fragments from pREP9-GHF-1
derivatives, corresponding to either wild-type GHF-1 or the Ala-115, Ala-220,
and Ala-115-220 mutants (see below), were inserted in frame into expression
vector pRSETA (Invitrogen). These constructs were used to express and purify,
through a ProBond resin (Invitrogen), recombinant polyhistidine-tagged GHF-1,
as well as its mutant versions, under nondenaturing conditions by following the
manufacturer’s suggestions.
Whole-cell GH3 extracts were prepared from PBS-washed cell pellets sus-
pended in NPB1PI (20 mM N-2-hydroxyethylpiperazine-N9-2-ethanesulfonic
acid [HEPES]-NaOH [pH 7.9], 140 mM NaCl, 2 mMMgCl2, 0.1% Triton X-100,
1 mM dithiothreitol, 20 mM b-glycerophosphate, 100 mM sodium orthovana-
date, 5 mM NaF, 2 mM sodium molybdate, 0.5 mM phenylmethylsulfonyl fluo-
ride, 1 mg of aprotinin per ml, 1 mg of leupeptin per ml, 100 mM benzamidine)
(100 ml/5 3 106 cells). After 10 min on ice, an equal volume of 23 DC (20 mM
HEPES-NaOH [pH 7.9], 50% glycerol, 840 mM NaCl, 1.5 mM MgCl2, 0.4 mM
EDTA, 1 mM dithiothreitol, 20 mM b-glycerophosphate, 100 mM sodium or-
thovanadate, 5 mM NaF, 2 mM sodium molybdate, 0.5 mM phenylmethylsulfo-
nyl fluoride, 1 mg of aprotinin per ml, 1 mg of leupeptin per ml, 100 mM
benzamidine) was added and the samples were rotated at 48C for 30 min. The
extracts were cleared by 10 min of centrifugation at 14,000 rpm and 48C in a
FIG. 1. The DNA binding activity of GHF-1 is cell cycle regulated. (A)
Electrophoretic mobility shift assays performed with GH3 whole-cell extracts.
Lanes: 1 and 2, exponentially growing cultures either untreated or treated with
nocodazole for 3 h, respectively, prior to extract preparation; 3 and 4, mitotic
cells isolated by the shake-off procedure (lane 4) after culture treatment with
nocodazole and nonmitotic cells that remained attached to the plate (lane 3).
Radiolabeled probes corresponding to high-affinity GHF-1 binding sites from the
GH (GH-1P), PRL (PRL-1P), and GHF-1 (GHF-1P) promoters were used. (B)
Immunoblot analysis done by using an anti-GHF-1 antibody to quantitate the
amount of GHF-1 present in the extracts tested in panel A (10 mg of total extract
protein per lane). (C) Electrophoretic mobility shift assay performed with ex-
tracts prepared from either exponentially growing GH3 cells (lane 1), mitotic
GH3 cells (lane 2) obtained by shaking off of nocodazole-treated cells, or mitotic
GH3 cells that were replated and harvested 3 h later (lane 3). The GH-1P site
was used as a probe. (D) The amount of GHF-1 present in the extracts (10 mg
each) used for panel C was determined by immunoblot analysis with an anti-
GHF-1 antibody.
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microcentrifuge, and the protein concentration was determined by the Bradford
assay.
Electrophoretic mobility shift assays were performed with 1 to 5 ng of recom-
binant protein or 1 mg of total extract protein and the probes previously de-
scribed (35).
Immunoblotting and antibodies. GHF-1 was detected in GH3 extracts (10 mg
per lane) by immunoblotting as previously described (35). Two different rabbit
anti-GHF-1 sera were used in this study. One has already been described (3). A
second rabbit anti-GHF-1 serum was generated against a peptide comprising
residues 274 to 285 of rat GHF-1. Similar results were obtained with both
antisera.
Metabolic labeling and immunoprecipitation. GH3 cells were incubated in
dialyzed fetal calf serum (5%)-supplemented, methionine-free, or phosphate-
free DMEM for 30 min before labeling. Cells were labeled for 1 h with Trans-
35S-label (ICN) (200 mCi/ml) or 32Pi (1 mCi/ml), respectively. After labeling,
plates were placed on ice and washed once with ice-cold PBS. One milliliter of
radioimmunoprecipitation assay buffer (5) was added, and the plates were incu-
bated on ice for 30 min. Radioimmunoprecipitation assay lysates were clarified
by centrifugation and immunoprecipitated with an excess of antibody as previ-
ously described (5). Protein A-Sepharose immune complexes were washed three
times with radioimmunoprecipitation assay buffer and fractionated by sodium
dodecyl sulfate (SDS)–12% polyacrylamide gel electrophoresis (PAGE). When
labeling was performed with 32Pi, after electrophoresis, the proteins were elec-
troblotted onto a nitrocellulose filter to continue with the phosphopeptide map-
ping (see below).
Tryptic phosphopeptide mapping. In vivo- and in vitro-phosphorylated GHF-1
was fractionated by SDS–12% PAGE, transferred to nitrocellulose by electrob-
lotting, and autoradiographically detected. Radiolabeled GHF-1 bands were
excised and digested with trypsin as previously described (25). The resulting
phosphopeptides were collected and resolved by electrophoresis with pH 1.9
buffer, followed by chromatography in phosphochromatography buffer (5).
Transfections. HindIII-NotI fragments from pBS-GHF-1 and its Ala-115, Ala-
220, and Ala-115-220 mutant derivatives were inserted into the pREP9 mam-
malian expression vector (Invitrogen) to generate pREP9-GHF-1(WT) and its
mutant derivatives. CV-1 cells on 35-mm-diameter plates were cotransfected by
using Lipofectamine (Gibco/BRL) with 100 ng of a 2422PRL-Luc (15) or
2312GH-Luc (35) reporter, along with 100 ng of pREP9 or the respective
pREP9-GHF-1 expression vector. Cells were incubated with 1025 M forskolin or
with ethanol (vehicle control) 33 h after transfection and harvested 3 h later to
determine luciferase activity.
In vitro kinase assays. Extracts (50 mg per reaction) of whole HeLa cells
prepared as described above were used to phosphorylate 200 mg of either wild-
type or Ala-115 or Ala-220 mutant recombinant polyhistidine–GHF-1. The re-
actions were performed in a 100-ml volume containing 20 mM HEPES-NaOH
(pH 7.6), 15 mM MgCl2, 2 mM ethylene glycol-bis(b-aminoethyl ether)-
N,N,N9,N9-tetraacetic acid (EGTA), 1 mM EDTA, 60 mM b-glycerophosphate,
5 mM dithiothreitol, 100 mM benzamidine, 20 mM ATP, and 5 mCi of
[g-32P]ATP and incubated for 30 min at 308C. The recombinant polyhistidine
proteins were isolated on Probond resin and, after elution with SDS-PAGE
sample buffer, fractionated by SDS-PAGE and autoradiographed. PKA phos-
phorylation reactions were performed in the same buffer as above with 100 ng of
substrate. Lactoglobulin (1 mg per reaction) was added as a carrier. Once the
reaction was concluded, the proteins were ethanol precipitated in the presence of
5 mg of bovine serum albumin and analyzed by SDS-PAGE and autoradiography
as described above. Alternatively, after phosphorylation, the DNA binding ac-
tivity of recombinant GHF-1 proteins was analyzed by electrophoretic mobility
shift assay.
RESULTS
The DNA binding activity of GHF-1 is cell cycle regulated.
Previous findings suggest that GHF-1 is required for prolifer-
FIG. 2. Phosphorylation of GHF-1 increases in mitotic cells. (A) Immuno-
precipitation of GHF-1 phosphorylated in vivo. Radioimmunoprecipitation assay
lysates of GH3 cells (107 cells per sample) that were pulse-labeled for 1 h with
32Pi prior to harvesting were immunoprecipitated with either preimmune serum
(lane 1) or anti-GHF-1 serum (lanes 2 to 7). The cells analyzed in lanes 1 and 2
were exponentially growing. The cells in lanes 3 to 7 were first synchronized at
the G1-S interphase by a thymidine block. In lane 3, 5 h after release from the
block, the cells were treated with nocodazole for 3 h prior to labeling. In lanes 4
to 7, the cells were labeled at 3, 6, 9, and 12 h after release of the thymidine block,
respectively. The immunoprecipitates were separated by SDS–12% PAGE,
transferred to nitrocellulose, and autoradiographed. The GHF-1-specific bands
are indicated by the arrows. Unlabeled samples of cells subjected to the same
treatments were analyzed on a FACScan, and the cell cycle distribution of each
population (based on DNA content) is shown in percentages at the bottom. The
numbers to the left are molecular sizes in kilodaltons. (B) Immunoprecipitation
of 35S-labeled GHF-1 from GH3 cells that were treated as described above and
GH3 cells that were pulse-labeled for 1 h with Trans-35S-label before harvesting.
Lanes: 1, immunoprecipitation with preimmune serum; 2 to 7, immunoprecipi-
tation with anti-GHF-1 serum. Following separation by SDS-PAGE, labeled
proteins were detected by fluorography. The results of FACScan analyses per-
formed with unlabeled samples of cultures subjected to the same treatments in
parallel with the labeled cultures are indicated at the bottom. The GHF-1 bands
are indicated by the arrows. n.s., nonspecific bands. The numbers to the left are
molecular sizes in kilodaltons. (C) Tryptic phosphopeptide maps of GHF-1
isolated from 32P-labeled GH3 cells. Exponentially growing (EG) and mitotic-
cell-enriched (M) populations of GH3 cells were labeled with 32Pi for 1 h prior
to harvesting. GHF-1 was isolated as described for panel A, and its 32P-labeled
bands (seen in lanes 2 and 3 of panel A) above were subjected to phosphopeptide
mapping. The amount of radioactivity analyzed was adjusted to reflect equal cell
numbers. Repeatedly detected phosphopeptides (seen in three different experi-
ments) are numbered. The origins of the maps are marked by arrowheads.
6696 CAELLES ET AL. MOL. CELL. BIOL.
 at CSIC-PUBLICACIO
NES ELECTRO
NICAS on M
ay 7, 2010 
m
cb.asm
.org
D
ow
nloaded from
 
ation of somatotropic and lactotropic cells (6, 22). This possi-
ble involvement in cell proliferation suggested that the DNA
binding activity of GHF-1 is cell cycle regulated, as previously
shown for Oct-1 (29, 30). We therefore used different protocols
to synchronize GH-synthesizing GH3 cells at different phases
of the cell cycle. Whole-cell extracts were prepared, and
GHF-1 DNA binding activity was measured by an electro-
phoretic mobility shift assay. These experiments revealed that
GHF-1 DNA binding activity was dramatically inhibited during
the M phase (Fig. 1A, lane 4). The degree of inhibition was not
influenced by the nature of the target site used to measure
GHF-1 binding. As enrichment for mitotic cells involved treat-
ment with the antimicrotubule drug nocodazole, we examined
the effect of the drug itself on GHF-1 DNA binding. A 3-h
incubation of exponentially growing cells with nocodazole did
not affect GHF-1 binding activity (lane 2), and even prolonged
incubation with the drug did not inhibit GHF-1 binding activity
in those cells that remained attached to the plate (lane 3). A
similar inhibition of GHF-1 DNA binding was observed in
mitotic cells selected by the shake-off procedure (37) without
drug treatment (data not shown). Immunoblotting of cell ex-
tracts revealed that the inhibition of GHF-1 DNA binding
activity was not due to degradation of the protein (Fig. 1B).
The inhibition of DNA binding activity was reversible, and 3 h
after replating of mitotic cells, GHF-1 binding activity was
restored nearly to the basal level (Fig. 1C and D). Similar
results were obtained with other GHF-1-expressing cells, in-
cluding GC, 235, and GHFT-1 cells, regardless of whether they
express GH, PRL, or neither (data not shown). We also ob-
served inhibition of Oct-1 and Oct-2 DNA binding activities in
mitotically enriched populations of B-JAB cells (unpublished
results).
Phosphorylation of GHF-1 increases in the M phase. The
inhibition of GHF-1 DNA binding during mitosis resembles
the mitotic inhibition of Oct-1 activity (29). As the mitotic
inhibition of Oct-1 activity is due to its phosphorylation (30),
we examined the cell cycle dependence of GHF-1 phosphory-
lation. GH3 cells that were synchronized at the G1-S-phase
boundary by a thymidine block were allowed to progress
through the cell cycle after removal of the drug. To enrich for
M-phase cells, 5 h after thymidine removal the cells were
treated with nocodazole for 3 h. A portion of the cells were
removed for flow-cytometric analysis of their DNA content,
and the rest were labeled with 32Pi. As shown in Fig. 2A, the
level of GHF-1 phosphorylation was lowest at the beginning of
the S phase (lane 4) and then began to increase as cells pro-
gressed through the cycle and reached the M phase (lanes 5
and 6). After the majority of the cells had traversed the M
phase, the level of GHF-1 phosphorylation declined (lane 7).
In the population highly enriched in mitotic cells (lane 3), the
level of GHF-1 phosphorylation was at least 10-fold higher
than in nonsynchronized cells (lane 2). A similar analysis, in
which [35S]methionine, instead of 32Pi, was used to label
GHF-1, indicated that its rate of synthesis was fairly uniform
throughout the cell cycle (Fig. 2B).
Two-dimensional tryptic phosphopeptide mapping indicated
FIG. 3. GHF-1 is phosphorylated at Ser-115 and Thr-220 in mitotic cells. Tryptic phosphopeptide maps of in vivo-phosphorylated GHF-1 isolated from GH3
cultures that were enriched in mitotic cells (A) and PKA-phosphorylated recombinant wild-type (WT) GHF-1 (B), GHF-1(Ala-115) (C), and GHF-1(Ala-220) (D).
Samples of tryptic digests of all four proteins were analyzed in parallel. Equivalent phosphopeptides are numbered as in Fig. 2C. The origin of each map is marked
by an arrowhead.
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that not only was the level of GHF-1 phosphorylation higher in
mitotic cells than in nonsynchronized cells, but also its pattern
was different (Fig. 2C). While four tryptic phosphopeptides,
labeled 1 to 4, were detected in GHF-1 isolated from nonsyn-
chronized cells, the same four and three additional tryptic
phosphopeptides were detected in M-phase cells. While the
intensity of phosphopeptide 2 was relatively invariant, the in-
tensities of the signals generated by phosphopeptides 1, 3, and
especially 4 were higher in mitotic cells. Tryptic phosphopep-
tide mapping of GHF-1 isolated from a population enriched in
early S-phase cells indicated that phosphopeptide 2 was the
predominant species (data not shown). As the cells progressed
through the cycle and the population became enriched in mi-
totic cells, the levels of the other phosphopeptides gradually
increased (data not shown). Similar results were obtained
when two different anti-GHF-1 antibodies were used and when
the level of each phosphopeptide was normalized to the
amount of protein analyzed instead of the cell number (data
not shown). Phosphoamino acid analysis of GHF-1 isolated
from exponentially growing or mitotic cells revealed the pres-
ence of only phosphoserine and phosphothreonine (data not
shown).
GHF-1 is phosphorylated at Ser-115 and Thr-220 during
mitosis. Both GHF-1 and Oct-1 can be phosphorylated in vitro
by PKA on sites that inhibit their binding to DNA (17, 30). In
Oct-1, the PKA phosphorylation sites are identical to the mi-
totic phosphorylation sites (30). Since our phosphopeptide
maps of GHF-1, isolated from either exponentially growing or
mitotic cells, seemed different from those of Kapiloff et al.
(17), we used our conditions to map GHF-1 phosphorylated in
vitro by PKA. We found that every single phosphopeptide
present in GHF-1 phosphorylated in mitotic cells, with the
exception of phosphopeptide 2, was also present in GHF-1
phosphorylated by PKA (Fig. 3A and B). Even the relative
intensities of the different phosphopeptides were, by and large,
similar in the two preparations of phospho-GHF-1.
PKA has been reported to phosphorylate GHF-1 on Ser-115
and Thr-220 (17). To confirm these results, we expressed and
purified two variant GHF-1 proteins, GHF-1(Ala-115) and
GHF-1(Ala-220). Both proteins were phosphorylated by PKA
and subjected to phosphopeptide mapping. While GHF-1(Ala-
115) lacked phosphopeptides 3, 4, 5, and 6, GHF-1(Ala-220)
contained these phosphopeptides but lacked phosphopeptides
1 and 7 (Fig. 3C and D). These results were also supported by
phosphoamino acid analysis, which revealed the presence of
phosphothreonine in spots 1 and 7 and phosphoserine in spots
3, 4, 5, and 6 (data not shown). Collectively, these results
indicate that PKA phosphorylated GHF-1 at Ser-115 and Thr-
220. These are also the sites subject to phosphorylation during
the M phase. The presence of multiple phosphopeptides cor-
responding to each of these phosphorylation sites is due to
partial tryptic digestion caused by the several adjacent posi-
tively charged residues that flank these sites.
Next we compared the effect of PKA on the DNA binding
activity of wild-type GHF-1 to its effect on GHF-1(Ala-115)
and GHF-1(Ala-220). While the binding of wild-type GHF-1
and GHF-1(Ala-115) to three different target sites derived
from either the GH, PRL, or GHF-1 gene was inhibited by
PKA-mediated phosphorylation, the DNA binding activity of
GHF-1(Ala-220) was resistant to inhibition (Fig. 4). Therefore,
as previously concluded by Kapiloff et al. (17), phosphorylation
at Thr-220 inhibits the binding of GHF-1 to DNA. However,
unlike those authors, we found that PKA phosphorylation in-
hibited the binding of GHF-1 to both GH- and PRL-derived
binding sites indiscriminately.
A mitotic kinase phosphorylates GHF-1 in vitro. The results
described so far indicate that in vitro GHF-1 is phosphorylated
by PKA on the same sites that are phosphorylated in vivo
during the M phase, with a sole exception (the site that ac-
counts for phosphopeptide 2). To investigate the relationship
between the mitotic GHF-1 kinase and PKA, we prepared
extracts of either nonsynchronized, exponentially growing or
M-phase-enriched whole HeLa cells. HeLa cells are a legiti-
mate source of this activity, as exactly the same mode of reg-
ulation observed for GHF-1 is exhibited by Oct-1 in these cells
(29, 30). Either wild-type GHF-1 or GHF-1(Ala-115-220) was
used as the substrate. As shown in Fig. 5A, neither protein was
efficiently phosphorylated by the nonsynchronized cell extract,
whereas wild-type GHF-1, but not the variant GHF-1(Ala-115-
220), was efficiently phosphorylated by the mitotic extract. Im-
munoblot analysis demonstrated that the lack of GHF-1 phos-
phorylation by the nonsynchronized cell extract is not due to its
degradation by this extract (Fig. 5A, bottom). Tryptic phos-
phopeptide mapping of GHF-1 phosphorylated by the mitotic
cell extract indicated that the pattern of phosphorylation was
identical to that obtained with PKA (Fig. 5B). Therefore, the
mitotic kinase phosphorylates GHF-1 in vitro on the same sites
that are phosphorylated during the M phase in vivo and has
substrate specificity similar to that of PKA.
Next we examined whether the GHF-1 kinase activity
present in the mitotic extract is sensitive to inhibition by pro-
tein kinase inhibitor (PKI), a specific inhibitor of PKA (41).
While addition of PKI to the phosphorylation reaction inhib-
ited the phosphorylation of GHF-1 by either PKA alone (90%
inhibition) or by PKA mixed with the mitotic extract (80%
inhibition), it had very little effect, if any, on the phosphoryla-
tion of GHF-1 by the kinase activity present in the mitotic
extract (Fig. 5C, compare lanes 1 and 2 to lanes 5 and 6).
PKA does not inhibit GHF-1 activity in vivo. To examine
whether activation of PKA in vivo has any effect on GHF-1
activity, we cotransfected CV-1 cells with a GHF-1 expression
vector and two GHF-1-dependent reporters, 2312GH-Luc
and 2422PRL-Luc. After transfection, the cells were incu-
bated in the absence or presence of forskolin, an activator of
FIG. 4. Phosphorylation of Thr-220 inhibits the binding of GHF-1 to its
target sites. Electrophoretic mobility shift assays were performed with recombi-
nant wild-type (WT) GHF-1 and the GHF-1(Ala-115) and GHF-1(Ala-220)
variants. The proteins were subjected to an in vitro phosphorylation by PKA in
the presence or absence of PKI, as indicated, prior to analysis of DNA binding.
In the reactions carried out in the absence of PKI, this peptide was added once
the phosphorylation reaction was completed. Oligonucleotides containing the
high-affinity GHF-1 binding sites of the GH (GH-1p), PRL (PRL-1p), and
GHF-1 (GHF-1P) promoters were used as probes.
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adenylyl cyclase that is known to stimulate GH promoter ac-
tivity in pituitary cells (9). Instead of inhibiting GHF-1 activity,
forskolin stimulated the activation of both the GH and PRL
promoters (Fig. 6). This stimulation, however, did not involve
phosphorylation of GHF-1, as the transcriptional activity of the
variant GHF-1(Ala-115-220) was also stimulated.
To examine whether activation of PKA stimulates the phos-
phorylation of GHF-1 in GH3 cells, we incubated 32P-loaded
cells with forskolin, nocodazole, or ethanol (vehicle control)
and isolated GHF-1 by immunoprecipitation. SDS-PAGE
analysis and autoradiography indicated that forskolin treat-
ment stimulated GHF-1 phosphorylation almost as efficiently
as incubation of cells with nocodazole (data not shown). How-
ever, when equal amounts of 32P-labeled GHF-1 isolated from
either forskolin- or nocodazole-treated GH3 cells were di-
gested with trypsin and subjected to two-dimensional phos-
phopeptide analysis, it was clear that forskolin did not stimu-
late the phosphorylation of Thr-220 (Fig. 7). While digestion of
32P-labeled GHF-1 isolated from nocodazole-treated cells gave
rise to all of the tryptic phosphopeptides seen before, including
phosphopeptides 1 and 7, which denote phosphorylation of
Thr-220, 32P-labeled GHF-1 recovered from forskolin-treated
cells was deficient in phosphopeptides 1 and 7. In fact, the
phosphopeptide map of GHF-1 from forskolin-stimulated cells
was very similar to that of GHF-1(Ala-220) phosphorylated in
vitro by PKA (Fig. 3). Thus, although forskolin treatment stim-
ulates the phosphorylation of GHF-1, Thr-220 is not one of the
affected sites.
DISCUSSION
As shown in this report, phosphorylation of GHF-1 at Thr-
220 inhibits its binding to DNA. However, by contrast to a
previous report (17) but consistent with the physiological con-
trol of GH expression, activation of PKA does not cause the
phosphorylation of GHF-1 at Thr-220. Instead, this site, re-
sponsible for inhibition of DNA binding, is phosphorylated by
a mitosis-specific kinase. Interestingly, Thr-220 is highly con-
served among members of the POU group of homeodomain
proteins, which contain either Ser or Thr at this position.
Indeed, phosphorylation of Oct-1, another POU protein, at
Ser-385, the counterpart of Thr-220 of GHF-1, also inhibits
DNA binding (30). This residue is located in the N-terminal
arm of the POU homeodomain (Ser-7 in the Oct-1 DNA
binding domain, whose structure was solved by Klemm et al.
[19]). Although Ser-385 is not in direct contact with the DNA,
residues located next to it contact the phosphates on the DNA
or make hydrogen bonds to phosphodiester oxygens (19).
Therefore, phosphorylation of this residue is likely to interfere
with DNA binding through electrostatic repulsions, a mecha-
nism similar to that proposed for inhibition of c-Jun binding to
DNA through phosphorylation of residues located next to its
basic region (5, 14, 23). Alternatively, phosphorylation of this
critical Ser or Thr residue may alter the conformation of the
N-terminal arm and disrupt its interaction with the minor
groove of the recognition site. By contrast to Kapiloff et al.
(17), we found that phosphorylation of GHF-1 at Thr-220
indiscriminately inhibited its binding to all of the target sites
tested, including sites such as PRL-1P and GHF1-1P (referred
to as PB-1 in reference 17), with which those authors observed
no effect of phosphorylation on binding activity. The indiscrim-
FIG. 5. GHF-1 kinase activity is enriched in mitotic cell extracts and is not
inhibited by PKI. (A) In vitro phosphorylation of wild-type GHF-1 (WT) and
GHF-1(Ala-115-220) (MUT) using extracts of either exponentially growing (EG)
or mitotic-cell-enriched (M) populations of HeLa cells. After the phosphoryla-
tion reactions were terminated, recombinant GHF-1 proteins were isolated on
Probond beads, fractionated by SDS-PAGE, and electroblotted to a nitrocellu-
lose membrane. Protein phosphorylation was detected by autoradiography (top),
and the total amount of recovered GHF-1 protein was determined by immuno-
blotting. (B) Tryptic phosphopeptide maps of recombinant wild-type GHF-1
phosphorylated by either PKA or the mitotic HeLa cell extract (M). The origin
of each map is indicated by the arrowhead. (C) Recombinant wild-type GHF-1
was phosphorylated in vitro by either a mitotic HeLa cell extract (lanes 1 and 2),
a mitotic-cell extract supplemented with PKA (lanes 3 and 4), or PKA alone
(lanes 5 and 6) in the absence or presence of PKI, as indicated. After isolation
of recombinant GHF-1 with Probond beads, its phosphorylation was analyzed by
SDS-PAGE and autoradiography. The GHF-1 band is indicated by the arrow.
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inate inhibition of DNA binding by phosphorylation at Thr-220
or its equivalent is entirely consistent with the important role
of the N-terminal arm in DNA binding (19) and the similar
effect of Ser-385 phosphorylation on binding of Oct-1 to its
target sites (30).
Another similarity between GHF-1 phosphorylation and
Oct-1 phosphorylation is their cell cycle dependence. Phos-
phorylation of Oct-1 at Ser-385 occurs as cells enter the M
phase and is reversed as cells reenter the G1 phase (29, 30).
Likewise, phosphorylation of GHF-1 at Thr-220 occurs upon
entry into the M phase, while reentry into G1 seems to be
associated with dephosphorylation of the site (Fig. 2). The
protein kinase that is responsible for Oct-1 phosphorylation
was not characterized. However, its mitotic phosphorylation
site is phosphorylated by PKA in vitro and therefore the mi-
totic kinase was proposed to be a PKA-like enzyme (30). While
the mitotic kinase that phosphorylates GHF-1 and Oct-1 rec-
ognizes sites that are also recognized by PKA in vitro (i.e., a
Ser or Thr residue preceded by several positively charged res-
idues; 18), we provide evidence suggesting that this protein
kinase is distinct from PKA. While PKA activity is inhibited by
the specific peptide inhibitor PKI (41), the mitotic kinase that
phosphorylates GHF-1 (and presumably also Oct-1) in vitro is
refractory to this inhibitor (Fig. 5). Since the pattern of regu-
lation and the substrate specificity of this in vitro activity are
identical to those of the mitotic kinase acting on GHF-1 and
Oct-1 in vivo, we presume that the two activities are the same.
We also found that activation of PKA in living cells does not
result in increased phosphorylation of Thr-220, although phos-
phorylation of other sites on GHF-1 is stimulated. It has not
been reported that PKA can phosphorylate Oct-1 in vivo either
or inhibit the activation of an Oct-1-dependent reporter gene.
Is the mitotic protein kinase activity that phosphorylates the
POU homeodomain related to previously identified mitotic
kinases? The best characterized mitotic protein kinase is Cdc2
(reviewed in references 12 and 28), which, like other members
of its family, recognizes a Ser or Thr residue followed by a Pro
at the P11 position while the P12 position shows preference
for a positively charged residue. The Pro at the P11 position is
strictly required for phosphorylation by Cdc2 or other cyclin-
dependent kinases (12, 18). However, the mitotic phosphory-
lation sites within the POU domains of GHF-1 and Oct-1 do
not contain Pro at P11. Thus, it is very unlikely that Cdc2 or
a related activity is responsible for phosphorylation of these
proteins. In agreement with these conclusions, GHF-1 was not
phosphorylated by Cdc2 in vitro (5a). Three sites that are
phosphorylated late in the M phase were detected on glial
fibrillary acidic protein, a component of intermediate fila-
ments. These sites are phosphorylated in vitro by PKA but not
by protein kinase C (26). Thus the glial fibrillary acidic protein
may be phosphorylated by the same mitotic kinase that phos-
phorylates the POU proteins.
The strict conservation of the mitotic phosphorylation site in
the POU protein suggests that it is of structural or regulatory
importance. Since the phosphoaccepting Ser residue is not
directly involved in contacting the octamer site (19), it is more
likely to have a regulatory role. A possible function for the
mitotic phosphorylation of POU proteins is their removal from
the DNA (chromatin) as cells enter mitosis. Indeed, analysis of
GH3 cells arrested early in mitosis by indirect immunofluores-
cence indicates that most of GHF-1 has been displaced from
the condensing chromatin (18a). As suggested by Segil et al.
(30), such displacement is likely to be involved in the general
transcriptional inhibition that occurs during the M phase (10).
In addition to their well-established role in transcription, POU
proteins may also be involved in cellular DNA replication. At
least one protein, Oct-1, plays a critical role in assembly of the
initiation complex at the origin of adenovirus replication (7).
Interference with GHF-1 expression inhibits the proliferation
of pituitary cells in vitro (6), and its inactivation through mu-
tations prevents the expansion of somatotropic-lactotropic
progenitors in vivo (6, 24), suggesting some involvement in cell
proliferation and, possibly, DNA replication. In that case, the
mitotic phosphorylation of such proteins may be responsible
for disassembly of origin recognition complexes. Reentry into
the G1 phase is associated with rapid dephosphorylation of the
mitotic phosphorylation sites, thus allowing POU proteins to
resume their transcriptional activation role, as well as their
putative replicative functions.
FIG. 6. PKA activation does not inhibit GHF-1 transcriptional activity. CV-1
cells were cotransfected with either the 2312GH-Luc or the 2422PRL-Luc
reporter and either an empty expression vector (pREP-9) or an expression vector
encoding wild-type (wt) GHF-1 or a mutant lacking PKA phosphorylation sites,
GHF-1(Ala-115-220). After 33 h, the cells were incubated with either ethanol
(vehicle control) or 10 mM forskolin (forsk) in ethanol. Cell extracts were pre-
pared 3 h later, and luciferase activity was determined. RLU, relative light units.
FIG. 7. PKA activation does not result in phosphorylation of Thr-220. 32P-
labeled GHF-1 was isolated from 32Pi-labeled GH3 cells treated with either
forskolin (Forsk; 10 mM for 30 min) or a thymidine block followed by nocodazole
(40 ng/ml for 3 h) prior to harvesting. Equal amounts of 32P-labeled protein were
digested with trypsin and subjected to two-dimensional analysis as described in
the legend to Fig. 3. An arrowhead indicates the origin of each map.
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